Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
63.66
+0.10 (0.16%)
At close: Mar 13, 2026, 4:00 PM EDT
63.55
-0.11 (-0.17%)
Pre-market: Mar 16, 2026, 8:00 AM EDT
Halozyme Therapeutics Revenue
In the year 2025, Halozyme Therapeutics had annual revenue of $1.40B with 37.55% growth. Halozyme Therapeutics had revenue of $451.77M in the quarter ending December 31, 2025, with 51.60% growth.
Revenue (ttm)
$1.40B
Revenue Growth
+37.55%
P/S Ratio
5.38
Revenue / Employee
$3,301,681
Employees
423
Market Cap
7.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | 381.29M | 37.55% |
| Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
| Dec 31, 2019 | 195.99M | 44.13M | 29.06% |
| Dec 31, 2018 | 151.86M | -164.75M | -52.04% |
| Dec 31, 2017 | 316.61M | 169.92M | 115.84% |
| Dec 31, 2016 | 146.69M | 11.63M | 8.61% |
| Dec 31, 2015 | 135.06M | 59.72M | 79.28% |
| Dec 31, 2014 | 75.33M | 20.54M | 37.47% |
| Dec 31, 2013 | 54.80M | 12.47M | 29.47% |
| Dec 31, 2012 | 42.33M | -13.76M | -24.54% |
| Dec 31, 2011 | 56.09M | 42.46M | 311.67% |
| Dec 31, 2010 | 13.62M | -47.19K | -0.35% |
| Dec 31, 2009 | 13.67M | 4.91M | 55.99% |
| Dec 31, 2008 | 8.76M | 4.96M | 130.66% |
| Dec 31, 2007 | 3.80M | 2.82M | 287.02% |
| Dec 31, 2006 | 981.75K | 854.54K | 671.76% |
| Dec 31, 2005 | 127.21K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Axsome Therapeutics | 638.50M |
| Krystal Biotech | 389.13M |
| ImmunityBio | 113.29M |
| Cytokinetics | 88.04M |
| Arcellx | 22.29M |
| Praxis Precision Medicines | 7.46M |
HALO News
- 3 days ago - Halozyme Appoints David Ramsay as Interim Chief Financial Officer - PRNewsWire
- 4 days ago - Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript - Seeking Alpha
- 5 days ago - Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 9 days ago - U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma - PRNewsWire
- 12 days ago - Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 18 days ago - Halozyme to Participate in Upcoming Investor Conferences - PRNewsWire
- 25 days ago - Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge - Seeking Alpha
- 26 days ago - Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript - Seeking Alpha